Juan J Badimon, PhD

 Dr. Juan Jose Badimon’s Biography

SPECIALTIES

Cardiovascular Diseases: Lipids, Thrombosis, Diagnosis, Prevention and Treatment
Professional Summary
Dr. Juan Badimon is an internationally recognized leader in cardiovascular research, with expertise in atherothrombosis, thrombosis, and heart failure. His work focuses on translational and clinical investigation, bridging mechanistic insights with therapeutic innovation, particularly through advanced imaging and metabolic approaches.

EDUCATION

1977 Licenciature in Pharmacy / Biochemistry. University of Barcelona
1977 Specialty in Pharmacology, School of Medicine. University of Barcelona and High Council for Scientific Research of Spain.
1980 Doctoral Thesis (Ph.D.)  Pharmacology/Biochemistry. Summa Cum Laude. University of Barcelona.

POSTDOCTORAL TRAINING

1981 Thrombosis and Atherosclerosis, Spanish National Research Council (
1982 Atherosclerosis Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota

ACADEMIC APPOINTMENTS.

1984-1990 Assistant Professor at the Mount Sinai School of Medicine, New York.
1991-1994 Assistant Professor Massachusetts General Hospital, Harvard University, Boston.
1994- 2001 Associated Professor at the Mount Sinai School of Medicine, New York .
2001 Present  Medicine/Cardiology and Director, Atherothrombosis Research Unit at the Valentin Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai.

RESEARCH INTERESTS:

•  Atherothrombosis and plaque vulnerability
•  Dyslipidemia and lipid lowering agents
•  Thrombosis, coagulation and antithrombotic agents
•  Heart failure (MRI-based endpoints)
•  Ischemia/reperfusion injury and metabolic remodeling
•  Cardiovascular effects of SGLT2 inhibitors

SCIENTIFIC CONTRIBUTIONS
Dr. Badimon’s research efforts have been focused to the study of the pathogenesis and treatment of atherosclerosis, thrombosis and cardiovascular diseases in general; more specifically on the mechanisms involved on the genesis, progression and disruption of the so-called vulnerable lesions  responsible for the onset of acute coronary syndromes (myocardial infarction, stroke, etc). These efforts have been undertaken taking advantage of the magnetic resonance imaging (MRI) techniques that allow the non-invasive detection and characterization of  atherosclerotic lesions We were the first to document the benefits of high-intensity statins doses on human atherosclerotic lesions using  MRI. Another area of interest was the postulated beneficial effect of high HDL levels against atherosclerotic disease. The discrepancy between the epidemiological/observational evidence and the lack of benefits of the HDL-targeted therapeutic approaches, generated the dogma of the differentiation between quality versus quantity of HDL levels.

This laboratory has been also instrumental in the study of novel therapeutic interventions directed towards the inhibition of the tissue Factor (TF) pathway. We have published several articles with direct inhibitors of the factors II (thrombin) and Xa of the coagulation cascade.

More recently, we are investigating the metabolic pathways involved in the adverse remodeling after ischemia/reperfusion. These studies are being undertaking both at the translational (porcine model) and clinical levels. The initial porcine studies were critical to demonstrate that the cardiovascular benefits of the SGLT2-inhibitrs, empagliflozin, were independent of its hypoglycemic activity. These studies were key for the design and performance of the EMPATROPISM trial (NCT 03485222). This mechanistic trial involving HFrEF patients without diabetes, showed that the SGLT2-inhibitors are an effective alternative for the treatment of HFrEF patients independently of their glycemic status. More recently, we have completed the SOTA-P-CARDIA trial (NCT 05562063) studying the effects of the dual SGLT1/2 inhibitor sotagliflozin in non-diabetic HFpEF patients

Mentorship.- Regarding his mentorship and training capabilities, his laboratory has trained more 50 Fellows from different countries. Most of them, following their stay with us, returned to their respective countries where they are independent researchers and most of them have achieved top level positions. 

Publications.- Dr. Badimon’s lab has published more than 450 peer-reviewed articles in top journals in thrombosis, atherosclerosis and cardiovascular diseases. The complete list of publications can be found here: https://pubmed.ncbi.nlm.nih.gov/?term=Badimon+J&sort=pubdate.

Dr. Badimon’s lab highlights

Dr. Juan Badimon and his team have made groundbreaking studies in several aspects of atherothrombosis and Cardiovascular Diseases research:
- Role of HDL-cholesterol in Atherosclerosis.(Lab Invest. 1989;60(3):455-61. and J Clin Invest. 1990;85(4):1234-41)
- Studies on   mechanism and optimal dose of several antithrombotic therapies by using the original Badimon perfusion chamber.( Methods Mol Biol. 2018;1816:161-171.)
- First studies showing the antiproliferative effect of Rapamycin. (Circulation. 1999;99(16):2164-70)
- First studies on the feasibility of MRI for monitoring the effects of different  interventions  J(ACC  2005;46:106-12)
-  The existence and role of a systemic pool of Tissue Factor in thrombosis. Studies that generated the interest in the inhibition of the TF pathway that lead to the  development of  the oral anticoagulants targeting Factor X, and thrombin (Proc Natl Acad Sci U S A. 1999;96(5):2311-5)
- The initial mechanistic study demonstrating that the benefits of the SGLT2-inhibitors in the treatment of HF are mediated via a glucose -independent mechanism. (J Am Coll Cardiol. 2021;77(3):243-255)

HONORS and AWARDS

2015 Honorary Member of the Royal National Academy of Pharmacy of Spain.
2019 Honorary Member of the Royal Academy of Pharmacy of Catalonia, Spain.
2025 Honorary Member of the Royal Academy of Pharmacy of the Reino de Aragon, Spain.

DOCTORATES HONORIS CAUSA
2001 Catholic University of Buenos Aires, Argentina.
2018 National University of Cordoba, Argentina.
2023 Universidad Cayetano Heredia, Lima. Peru.

FELLOWSHIPS
American College of Cardiology - FACC
American Heart Association (Thrombosis and Arteriosclerosis Council)- FAHA
European Society of Cardiology - FESC

HONORARY PROFESSORSHIPS
National University of Colombia
Tucuman School of Medicine. Argentina
University del Salvador, Buenos Aires, Argentina
University of the Aconcagua. Argentina
University of El Salvador, Buenos Aires, Argentina
University Cayetano Heredia, Lima, Peru

HONORARY MEMBER OF THE FOLLOWING PROFESSIONAL SOCIETIES

National Cardiology Societies of :
Argentina (SAC and FAC), Bolivia, Chile, Colombia, Mexico, Peru, Spain,
Local Cardiology Societies of San Luis, Tucuman and Los Andes in Argentina
Argentinian Society of Lipids
Atherosclerosis and Endothelium Society of Ecuador
Spanish Society of Arteriosclerosis
Scientific Board of the Spanish Familial Hypercholesterolemia Foundation.

OTHER AWARDS
1987 Annenberg Scholar in Cardiology
1989 Dr. Hermman C.B. and Suzanne Denber Award for Excellence in Cardiovascular Research.
1989 Sara Chayt Memorial Foundation Scholar
1997 VIIth Intern. Award of the Sanofi Association for Thrombosis and Haemostasis, Florence, Italy
2003 Xth Joan D’Alos Award. Clinic Saint Jordi. Barcelona. Spain
2004 2nd Pedro Maroto’s Lecture. Castellian Society of Cardiology
La Rebotica Award Spanish Royal Academy of Pharmacy
2006 Recipient of the John Paul II Medal.  Krakow. Poland.
2013 Simon Dack Award for Outstanding Scholarship. ACC

OTHER PROFESSIONAL APPOINTMENTS

Major Committee Assignments
1990-Present Reviewer for Grants and Application the Commission Interministerial de Ciencia y Tecnologia (Grant Reviewing Agency of Spain)
Reviewer for Grants. Veterans Administration
Reviewer for Grants and Application. National Heart, Lung and Blood Institute.  NIH
Reviewer for Grants NIH/NHLBI AIDS Basic Science RFA

Editorial Boards
Cardiovascular Drug and Therapy (Asociate Editor)
Reviews in Cardiovascular Medicine
Journal of Thrombosis and Haemostasis
Current Cardiology Review
Revista Española de Cardiologia
JACC (Pharmacology) 2016-2024

Frequent reviewer for
New England Journal of Medicine
JAMA
Circulation Research
Circulation
Journal of Clinical Investigation
Archives of Internal Medicine
European Heart Journal
Atherosclerosis
Atherosclerosis, Thrombosis and Vascular Biology
Journal of the American Heart Association
Journal of Cardiovascular Pharmacology
Thrombosis Research
among others cardiovascular journals

CLINICAL TRIALS DONE AS PRINCIPAL INVESTIGATOR.-
1.- Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution MRI.
2.- Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor+Aspirin versus Clopidogrel + Aspirin when Administered with Bivalirudin. (NCT01642238)
3.- Open Label Study in Healthy Adults Investigating the Antithrombotic Effects of a New Reversible P2Y12 Inhibitor BR-5224 vs Placebo using an Ex Vivo Model of Thrombosis.
4.- Antithrombotic Effects of 3 Novel Dual FIIa/ FXa Inhibitors versus FIIa-Inhibition and FXa Inhibition Alone: An Open Label Ex vivo Study in Healthy Volunteers.
5.- An Open-Label Study to Assess the antithrombotic effects of BMS-561389 in an Experimental Ex Vivo perfusion system.
6.- A Phase-I, Open-Label Study in Healthy Adult Male and Female Subjects to Assess the Antithrombotic Effect Following a Single Dose of DU-176b, an Oral Direct Factor Xa Inhibitor, Using an Ex Vivo Human Model of Thrombosis.
7.- A Phase-I, Randomized, Assessor-Blinded, Four-treatment, Three-Period, Incomplete Block Crossover Study in Healthy Adult Male and Female Subjects to Assess the Antithrombotic Effect of Single Oral Doses Of DZ-697b Compared to Clopidogrel Using an Ex Vivo Human Model of Thrombosis.
8.- An Open-Label, Pilot Study in Healthy Adult Subjects to Assess the Antithrombotic Effects of Two Doses of LA-419, A Novel NO-Donor, versus Abciximab.
9.- A Pharmacodynamic Comparison of Prasugrel versus High Dose Clopidogrel in Subjects with Type 2 Diabetes Mellitus and Coronary Artery Disease.
10.- Restoration of Platelet Function Following a Loading Dose of Prasugrel - An in vitro Study Utilizing Homologous Platelet Supplementation.
11.- Double-Blind, Crossover, Randomized Study to Assess the Antithrombotic Effect of Clopidogrel (75mg) with Aspirin (75mg) In Comparison With Clopidogrel (75mg) Alone and Aspirin (75mg) Alone After Repeated Administration in Healthy Volunteers.
12.- Effect of Platelet Concentrates on Platelet Reactivity of Subjects on chronic Clopidogrel and Aspirin Treatment.
13.- Effects of Treatment with Angiotensin-II Receptor Blocker Candesartan on Ex Vivo Thrombus Formation in Coronary Artery Disease Patients.
14.- An in vitro Study to Investigate the Effects of 3 doses of Dronedarone and 3 doses of its Active Metabolite SR35021A on Platelet Reactivity of Coronary Artery Disease Patients.
15.- Case-Control Study to Compare the Platelet Reactivity of Depressed versus Non-depressed Patients with Coronary Artery Disease - Translational Studies of Depression, Platelets and CAD.
16.- Translational Studies of Depression, Platelets and CAD. Platelet Reactivity in Coronary Artery Disease Patients with Depression: In-Vitro Comparison of four antidepressants on Platelet Reactivity
17.- Randomized Controlled Trial to Compare the in vivo Effects of SSRIs, 5-HT2A Receptor Antagonists and Cognitive Behavioral Therapy (CBT) On Platelet Reactivity, Thrombosis and Platelet 5-HT2A Receptor Density In Depressed CAD Patients.
18.- Study of  Antithrombotic Effects of Ticagrelor and Clopidogrel in T2DM. (NCT01823510)
19.- Reversing Ticagrelor's Antithrombotic Effects with Fresh Platelets. (NCT02201394).
20.- EMPA-TROPISM Trial:  Are the “cardiac benefits” of Empagliflozin independent of its hypoglycemic activity?  (ATRU-4). (NCT03485222)
21.- SOTA-P-CARDIA Trial (ATRU-V) A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes. (NCT05562063)
22.- SOTA-THROMBOSIS Trial (ATRU-VI)Antithrombotic Activities of Sotagliflozin vs. Empagliflozin (NCT06618976)

Doctoral Thesis directed:

1999 Dr. Randolph Hutter.  Mechanism of plaque rupture and atherosclerosis regression. Experimental and human evidence. University of Berlin.
Summa Cum Laude.

2004 Dr. Merce Roque  Identification of the mechanisms of inflammation and cellular proliferation involved in restenotic response using a model of intimal hyperplasia.   University of Barcelona Summa Cum Laude

2009 Dr. Borja Ibanez  Effect of the infusion of recombinant HDL (Apo A-I Milano) in an experimental rabbit model of atherosclerosis. University of Madrid  
Summa Cum Laude

2012 Dr. Susana Prat.   Cardioprotective effect of Metoprolol in the coronary reperfusion. Analysis of the isquemic myocardium by cardiac magnetic resonance.University of Barcelona
Summa Cum Laude

2012 Dr. Carlos Santos-Gallego  Autonomous University of Madrid Summan Cum Laude

2020 Dr. Alvaro Garcia-Ropero   Empagliflozin improves myocardial fibrosis and diastolic function in a non-diabetic porcine model of ischaemic heart failure. University of Madrid.
Summa Cum Laude

2026 Dr. Juan Antonio Requena-Ibanez   To be defended in September